Latest information on COVID-19
Support teaching, research, and patient care.
Research interest in the role of the central nervous system in female hypoactive sexual desire disorder.
24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder
This trial is designed to assess the safety and efficacy of flibanserin in the treatment of
premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard
diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Howden, 6504986128.
View full details